KR101054247B1 - 정제된 요산산화효소 제제 및 이를 포함한 조성물, 그리고 그 정제법 - Google Patents

정제된 요산산화효소 제제 및 이를 포함한 조성물, 그리고 그 정제법 Download PDF

Info

Publication number
KR101054247B1
KR101054247B1 KR1020087024272A KR20087024272A KR101054247B1 KR 101054247 B1 KR101054247 B1 KR 101054247B1 KR 1020087024272 A KR1020087024272 A KR 1020087024272A KR 20087024272 A KR20087024272 A KR 20087024272A KR 101054247 B1 KR101054247 B1 KR 101054247B1
Authority
KR
South Korea
Prior art keywords
uricase
aggregates
peg
octamer
uricases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020087024272A
Other languages
English (en)
Korean (ko)
Other versions
KR20080098686A (ko
Inventor
메리 알. 셔먼
마아크 지. 피. 사이퍼
엘. 데이비드 윌리엄스
마이클 에스. 허쉬필드
수잔 제이. 켈리
Original Assignee
듀크 유니버서티
마운틴 뷰 파마슈티컬즈 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 듀크 유니버서티, 마운틴 뷰 파마슈티컬즈 인크. filed Critical 듀크 유니버서티
Publication of KR20080098686A publication Critical patent/KR20080098686A/ko
Application granted granted Critical
Publication of KR101054247B1 publication Critical patent/KR101054247B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
    • C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020087024272A 2000-02-10 2001-02-07 정제된 요산산화효소 제제 및 이를 포함한 조성물, 그리고 그 정제법 Expired - Lifetime KR101054247B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/501,730 2000-02-10
US09/501,730 US6783965B1 (en) 2000-02-10 2000-02-10 Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
PCT/US2001/040069 WO2001059078A2 (en) 2000-02-10 2001-02-07 Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020027010189A Division KR100884724B1 (ko) 2000-02-10 2001-02-07 비면역원성 중합체 컨쥬게이트의 제조를 위한 응집체 없는 요산산화효소

Publications (2)

Publication Number Publication Date
KR20080098686A KR20080098686A (ko) 2008-11-11
KR101054247B1 true KR101054247B1 (ko) 2011-08-08

Family

ID=23994789

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020087024272A Expired - Lifetime KR101054247B1 (ko) 2000-02-10 2001-02-07 정제된 요산산화효소 제제 및 이를 포함한 조성물, 그리고 그 정제법
KR1020027010189A Expired - Lifetime KR100884724B1 (ko) 2000-02-10 2001-02-07 비면역원성 중합체 컨쥬게이트의 제조를 위한 응집체 없는 요산산화효소
KR1020077018682A Ceased KR20070092329A (ko) 2000-02-10 2001-02-07 비면역원성 중합체 컨쥬게이트의 제조를 위한 응집체 없는요산산화효소

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020027010189A Expired - Lifetime KR100884724B1 (ko) 2000-02-10 2001-02-07 비면역원성 중합체 컨쥬게이트의 제조를 위한 응집체 없는 요산산화효소
KR1020077018682A Ceased KR20070092329A (ko) 2000-02-10 2001-02-07 비면역원성 중합체 컨쥬게이트의 제조를 위한 응집체 없는요산산화효소

Country Status (27)

Country Link
US (3) US6783965B1 (enExample)
EP (3) EP1254237B1 (enExample)
JP (2) JP5165826B2 (enExample)
KR (3) KR101054247B1 (enExample)
CN (2) CN101735991B (enExample)
AT (1) ATE463576T1 (enExample)
AU (3) AU4997501A (enExample)
BE (1) BE2013C045I2 (enExample)
BR (1) BRPI0108386B8 (enExample)
CA (1) CA2398679C (enExample)
CY (3) CY1110142T1 (enExample)
CZ (1) CZ304864B6 (enExample)
DE (1) DE60141742D1 (enExample)
DK (3) DK2196538T3 (enExample)
ES (2) ES2343105T3 (enExample)
FR (1) FR13C0036I2 (enExample)
HU (1) HU227127B1 (enExample)
IL (3) IL151065A0 (enExample)
LU (1) LU92237I2 (enExample)
MX (1) MXPA02007545A (enExample)
NZ (1) NZ520434A (enExample)
PL (1) PL208064B1 (enExample)
PT (2) PT1254237E (enExample)
RU (3) RU2352354C2 (enExample)
TW (2) TWI322184B (enExample)
WO (1) WO2001059078A2 (enExample)
ZA (1) ZA200207206B (enExample)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
PL202799B1 (pl) * 1998-08-06 2009-07-31 Mountain View Pharmaceuticals Sposób izolowania urykazy w postaci tetramerycznej oraz wyizolowana tetrameryczna urykaza
US20060188971A1 (en) * 1998-08-06 2006-08-24 Duke University Urate oxidase
CA2338665C (en) 1998-08-06 2011-01-18 Mountain View Pharmaceuticals, Inc. Peg-urate oxidase conjugates and use thereof
BRPI9913360B8 (pt) 1998-08-06 2021-05-25 Univ Duke proteína de uricase recombinante quimérica, molécula de ácido nucléico isolada e purificada, vetor e célula hospedeira transformada.
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
ATE414711T1 (de) 2001-06-28 2008-12-15 Mountain View Pharmaceuticals Polymerstabilisierte proteinasen
US6913915B2 (en) 2001-08-02 2005-07-05 Phoenix Pharmacologics, Inc. PEG-modified uricase
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
ATE528014T1 (de) 2002-06-07 2011-10-15 Dyax Corp Polypeptid mit modifizierten kunitz domains
US8129330B2 (en) * 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US20040062748A1 (en) 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
WO2004060299A2 (en) * 2002-12-26 2004-07-22 Mountain View Pharmaceuticals, Inc. Polymer conjugates of interferon-beta with enhanced biological potency
JP2007500218A (ja) 2003-05-12 2007-01-11 アフィーマックス・インコーポレイテッド ポリ（エチレングリコール）修飾ペプチド系化合物の新規スペーサー部分
EP1625156B1 (en) * 2003-05-12 2012-09-19 Affymax, Inc. Peptides that bind to the erythropoietin receptor
EP1626983B8 (en) * 2003-05-12 2010-12-22 Affymax, Inc. Novel poly (ethylene glycol) modified erythropoietin agonists and uses thereof
ES2447423T3 (es) * 2003-08-29 2014-03-12 Dyax Corp. Inhibidores de proteasa poli-pegilados
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
WO2006062685A2 (en) * 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
KR20070108140A (ko) * 2004-11-11 2007-11-08 아피맥스, 인크. 에리트로포이에틴 수용체에 결합하는 신규한 펩타이드
JP2008534640A (ja) * 2005-04-05 2008-08-28 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー タンパク質の機能部位またはエピトープの遮蔽方法
PT3321359T (pt) 2005-04-11 2021-03-11 Horizon Pharma Rheumatology Llc Formas variantes de urato-oxidase e a sua utilização
WO2008051178A2 (en) * 2006-04-12 2008-05-02 Savient Pharmaceuticals, Inc. Purification of proteins with cationic surfactant
US20080159976A1 (en) * 2005-04-11 2008-07-03 Jacob Hartman Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
EP1871877A2 (en) * 2005-04-11 2008-01-02 Savient Pharmaceuticals, Inc. A variant form of urate oxidase and use thereof
US8148123B2 (en) * 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
TWI418564B (zh) * 2005-04-11 2013-12-11 Savient Pharmaceuticals Inc 利用陽離子界面活性劑之蛋白質純化
JP2008545665A (ja) * 2005-05-23 2008-12-18 ユニベルシテ ドゥ ジュネーブ 高体温による処置のための注入可能な超常磁性ナノ粒子および高体温インプラントを形成するための使用
US7919461B2 (en) 2005-06-03 2011-04-05 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US8324159B2 (en) * 2005-06-03 2012-12-04 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7550433B2 (en) 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
WO2009026334A2 (en) * 2007-08-21 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
JP2013516389A (ja) 2009-01-06 2013-05-13 ダイアックス コーポレーション カリクレイン阻害剤による粘膜炎治療
SG176897A1 (en) 2009-06-25 2012-01-30 Savient Pharmaceuticals Inc Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
ES2905545T3 (es) 2010-01-06 2022-04-11 Takeda Pharmaceuticals Co Proteínas de unión a calicreína plasmática
US8940861B2 (en) 2010-04-08 2015-01-27 Georgia Tech Research Corporation Variants of ancestral uricases and uses thereof
IL269565B2 (en) 2011-01-06 2024-06-01 Dyax Corp Plasma kallikrein binding proteins
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
US11077238B2 (en) * 2013-06-07 2021-08-03 Allena Pharmaceuticals, Inc. Compositions, methods, and devices for dialysis
WO2015003355A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CA2917671A1 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. 2,4-or 4,6-diaminopyrimidine compounds as idh2 mutants inhibitors for the treatment of cancer
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
CA2942072C (en) 2014-03-14 2022-07-26 Agios Pharmaceuticals, Inc. Pharmaceutical compositions and use of (s)-1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-1-( 4-cyanopyridin-2-yl)-n-( 5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide
EP3122782A4 (en) 2014-03-27 2017-09-13 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
CN107614007B (zh) 2015-05-15 2022-03-25 免疫医疗有限责任公司 改进的尿酸酶序列和治疗方法
MA71411A (fr) 2015-10-15 2025-04-30 Les Laboratoires Servier Polythérapie pour le traitement de tumeurs malignes
DK3362066T3 (da) 2015-10-15 2021-11-22 Les Laboratoires Servier Sas Kombinationsterapi til behandling af maligniteter
CN116077648A (zh) 2015-12-11 2023-05-09 武田药品工业株式会社 血浆激肽释放酶抑制剂及其治疗遗传性血管性水肿发作的用途
WO2018089808A1 (en) 2016-11-11 2018-05-17 Horizon Pharma Rheumatology Llc Combination therapies of prednisone and uricase molecules and uses thereof
JP2020530282A (ja) 2017-07-07 2020-10-22 アレナ ファーマシューティカルズ， インコーポレイテッド 組換えウリカーゼ酵素
US20190309269A1 (en) 2018-03-20 2019-10-10 Rubius Therapeutics, Inc. Therapeutic cell systems and methods for treating hyperuricemia and gout
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
CN109055260B (zh) * 2018-08-08 2021-11-09 淮海工学院 弯曲芽孢杆菌alkaAU及产尿酸氧化酶方法、产品与应用
WO2020160325A1 (en) 2019-01-30 2020-08-06 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
US12121566B2 (en) 2019-01-30 2024-10-22 Horizon Therapeutics Usa, Inc. Methods for treating gout
KR20250041198A (ko) * 2019-05-10 2025-03-25 피이지-바이오 바이오팜 컴퍼니 리미티드 (총칭) 폴리에틸렌 글리콜로 변형된 요산 산화효소
MX2023001740A (es) 2020-08-10 2023-04-05 Horizon Therapeutics Usa Inc Metodos de tratamiento de la gota.
CN114181917B (zh) * 2022-02-14 2022-06-03 潍坊华卓生物科技有限公司 一种改造尿酸酶、基因序列、制备方法及应用
CN117051026A (zh) * 2022-05-06 2023-11-14 江苏恰瑞生物科技有限公司 一种特异性尿酸结合物固定化树脂及其制备方法和应用
US12269875B2 (en) 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE279486C (enExample)
FR6301M (enExample) * 1967-03-29 1968-09-09
US3616231A (en) 1968-11-14 1971-10-26 Boehringer Mannheim Gmbh Process for the production of uricase
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5599189A (en) 1979-01-22 1980-07-28 Mihama Hisaharu Modified uricase free from antigenicity and its preparation
JPS55135590A (en) 1979-04-05 1980-10-22 Mihama Hisaharu Modified asparaginase and uricase and their preparation
CH657141A5 (de) 1980-07-01 1986-08-15 Hoffmann La Roche Dns-sequenzen, rekombinante expressionsvektoren zur mikrobiellen herstellung von human-leukozyten-interferonen und transformierte mikroorganismen.
JPS57192435A (en) 1981-05-20 1982-11-26 Toyobo Co Ltd Modified polypeptide
DE3126759A1 (de) 1981-07-07 1983-01-27 Boehringer Mannheim Gmbh, 6800 Mannheim Loesliche leber-uricase, verfahren zu ihrer herstellung und verwendung
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
DE3676670D1 (de) * 1985-06-26 1991-02-07 Cetus Corp Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung.
US4847079A (en) 1985-07-29 1989-07-11 Schering Corporation Biologically stable interferon compositions comprising thimerosal
DD279486A1 (de) 1986-03-10 1990-06-06 Akad Wissenschaften Ddr Verfahren zur aktivierung von hydroxylgruppenhaltigen polymeren verbindungen
JPS6255079A (ja) * 1986-04-23 1987-03-10 Mihama Hisaharu 修飾ウリカ−ゼ
JPH085506B2 (ja) * 1986-08-25 1996-01-24 日東製器株式会社 缶容器
DD279489A1 (de) 1986-12-11 1990-06-06 Leuna Werke Veb Verfahren zur herstellung optisch transparenter epoxidharzformmassen
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US4847325A (en) 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US5955336A (en) * 1988-08-17 1999-09-21 Toyo Boseki Kabushiki Kaisha DNA sequence for uricase and manufacturing process of uricase
US5349052A (en) 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
NZ234453A (en) * 1989-07-13 1993-01-27 Sanofi Sa Recombinant dna encoding urate oxidase, and vector, host, protein and pharmaceutical compositions associated therewith
KR0159107B1 (ko) 1989-07-13 1998-11-16 쟝 르쌍드뢰 우레이트 산화효소 활성 단백질, 이 단백질을 암호화하는 재조합 유전자, 발현 벡터, 미생물 및 형질전환세포
US5286637A (en) 1989-08-07 1994-02-15 Debiopharm, S.A. Biologically active drug polymer derivatives and method for preparing same
JPH03148298A (ja) 1989-11-01 1991-06-25 Sumitomo Pharmaceut Co Ltd 修飾ペプチドおよびその製造方法
SU1730145A1 (ru) * 1990-05-04 1992-04-30 Всесоюзный научно-исследовательский институт текстильно-галантерейной промышленности Способ стабилизации уриказы
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5653974A (en) 1990-10-18 1997-08-05 Board Of Regents,The University Of Texas System Preparation and characterization of liposomal formulations of tumor necrosis factor
ES2199935T3 (es) * 1991-03-15 2004-03-01 Amgen Inc. Pegilacion de polipeptidos.
CA2112674C (en) 1991-07-02 2005-10-04 John S. Patton Method and device for delivering aerosolized medicaments
WO1994019007A1 (en) 1993-02-16 1994-09-01 Enzon, Inc. Ribosome inactivating protein compositions having reduced antigenicity
WO1994023740A1 (en) * 1993-04-22 1994-10-27 Celtrix Pharmaceuticals, Inc. Conjugates of growth factor and bone resorption inhibitor
WO1995000162A1 (en) 1993-06-21 1995-01-05 Enzon, Inc. Site specific synthesis of conjugated peptides
IT1265101B1 (it) * 1993-07-23 1996-10-30 Erba Carlo Spa Derivati dell'acido 2-ammino-4-fenil-4-osso butirrico
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
ATE214940T1 (de) 1993-11-10 2002-04-15 Enzon Inc Verbesserte interferon-polymerkonjugate
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
AU697440B2 (en) 1994-12-07 1998-10-08 Novozymes A/S Polypeptide with reduced allergenicity
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
JP2758154B2 (ja) 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー インターフェロンを含む液体製剤
FR2733914B1 (fr) * 1995-05-11 1997-08-01 Sanofi Sa Composition de liquide stable contenant de l'urate oxydase et composition lyophilisee pour sa preparation
US5853974A (en) 1995-06-07 1998-12-29 Chiron Corporation Enhancement of alkaline phosphatase with SDS in chemiluminescent substrates
JPH09154581A (ja) 1995-12-05 1997-06-17 Asahi Chem Ind Co Ltd ウリカーゼを生産する実質上純粋な微生物
JP4295831B2 (ja) 1997-01-15 2009-07-15 ポラリス・グループ 改変された腫瘍壊死因子
DE69919701T2 (de) * 1998-06-01 2005-09-15 Genentech, Inc., South San Francisco Abtrennung von antikörper-monomeren von deren multimeren mittels ionaustausch-chromatographie
CA2338665C (en) * 1998-08-06 2011-01-18 Mountain View Pharmaceuticals, Inc. Peg-urate oxidase conjugates and use thereof
PL202799B1 (pl) 1998-08-06 2009-07-31 Mountain View Pharmaceuticals Sposób izolowania urykazy w postaci tetramerycznej oraz wyizolowana tetrameryczna urykaza
BRPI9913360B8 (pt) 1998-08-06 2021-05-25 Univ Duke proteína de uricase recombinante quimérica, molécula de ácido nucléico isolada e purificada, vetor e célula hospedeira transformada.
US6783965B1 (en) * 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
US6425448B1 (en) 2001-01-30 2002-07-30 Cdx Gas, L.L.P. Method and system for accessing subterranean zones from a limited surface area
US6913915B2 (en) 2001-08-02 2005-07-05 Phoenix Pharmacologics, Inc. PEG-modified uricase
US9917514B2 (en) 2013-05-24 2018-03-13 Idt Europe Gmbh Non PWM digital DC-DC converter

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Plant Physiology(1991)Vol.95, pp384-389.
Planta(1997)Vol.202, No.3, pp277-283.

Also Published As

Publication number Publication date
CN100491532C (zh) 2009-05-27
US7927852B2 (en) 2011-04-19
KR100884724B1 (ko) 2009-02-19
CN101735991A (zh) 2010-06-16
CN1423699A (zh) 2003-06-11
CZ304864B6 (cs) 2014-12-17
IL151065A0 (en) 2003-04-10
WO2001059078A2 (en) 2001-08-16
BR0108386C1 (pt) 2011-12-20
IL193365A (en) 2011-08-31
EP2196538B1 (en) 2014-10-01
FR13C0036I1 (fr) 2013-08-09
EP2305819B1 (en) 2014-11-12
CA2398679A1 (en) 2001-08-16
JP5341945B2 (ja) 2013-11-13
MXPA02007545A (es) 2002-12-13
CA2398679C (en) 2015-11-17
EP1254237B1 (en) 2010-04-07
US20080057048A1 (en) 2008-03-06
ES2343105T3 (es) 2010-07-23
KR20070092329A (ko) 2007-09-12
US6783965B1 (en) 2004-08-31
EP1254237A2 (en) 2002-11-06
HUP0204544A2 (en) 2003-05-28
RU2009104003A (ru) 2010-08-20
HK1144701A1 (en) 2011-03-04
DK2305819T3 (en) 2015-01-05
HK1056742A1 (zh) 2004-02-27
DE60141742D1 (de) 2010-05-20
US8921064B2 (en) 2014-12-30
JP5165826B2 (ja) 2013-03-21
BR0108386B1 (pt) 2017-10-31
DK2196538T3 (en) 2015-01-05
CZ20022982A3 (cs) 2003-01-15
TW200914617A (en) 2009-04-01
CN101735991B (zh) 2013-09-11
HU227127B1 (en) 2010-07-28
ZA200207206B (en) 2003-05-06
CY1110142T1 (el) 2015-01-14
AU2001249975B2 (en) 2006-06-08
JP2003521937A (ja) 2003-07-22
RU2557318C9 (ru) 2015-09-10
FR13C0036I2 (fr) 2014-05-16
IL151065A (en) 2008-12-29
KR20020087934A (ko) 2002-11-23
RU2557318C2 (ru) 2015-07-20
PT1254237E (pt) 2010-06-07
WO2001059078A3 (en) 2002-03-07
CY1117264T1 (el) 2017-04-26
JP2011188861A (ja) 2011-09-29
HK1143989A1 (en) 2011-01-21
NZ520434A (en) 2004-05-28
EP2196538A1 (en) 2010-06-16
ATE463576T1 (de) 2010-04-15
AU2009212900A1 (en) 2009-10-01
KR20080098686A (ko) 2008-11-11
ES2524153T3 (es) 2014-12-04
TWI322184B (en) 2010-03-21
HUP0204544A3 (en) 2007-05-02
IL193365A0 (en) 2009-02-11
EP2305819A1 (en) 2011-04-06
ES2343105T8 (es) 2013-07-15
AU4997501A (en) 2001-08-20
BRPI0108386B8 (pt) 2021-05-25
RU2352354C2 (ru) 2009-04-20
PL208064B1 (pl) 2011-03-31
CY2013028I2 (el) 2015-11-04
CY2013028I1 (el) 2015-11-04
LU92237I2 (fr) 2013-09-03
BR0108386A (pt) 2002-10-29
DK1254237T3 (da) 2010-07-19
BE2013C045I2 (enExample) 2020-06-24
PL358539A1 (en) 2004-08-09
AU2009212900B2 (en) 2011-12-08
US20110287466A1 (en) 2011-11-24
RU2006107110A (ru) 2007-09-20
PT2305819E (pt) 2015-06-01
RU2281954C2 (ru) 2006-08-20
HK1155203A1 (en) 2012-05-11

Similar Documents

Publication Publication Date Title
KR101054247B1 (ko) 정제된 요산산화효소 제제 및 이를 포함한 조성물, 그리고 그 정제법
US20180223263A1 (en) Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
AU2001249975A1 (en) Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
AU2006203252B8 (en) Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
HK1056742B (en) Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
HK1144701B (en) Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
HK1155203B (en) Conjugates prepared with aggregate-free proteins
HK1143989B (en) Conjugates prepared with aggregate-free proteins

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20081002

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20090106

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20090827

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20090106

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20090925

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20090827

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20110513

Appeal identifier: 2009101008912

Request date: 20090925

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20090925

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20090925

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20090406

Patent event code: PB09011R02I

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20091127

Patent event code: PE09021S01D

B601 Maintenance of original decision after re-examination before a trial
PB0601 Maintenance of original decision after re-examination before a trial
J301 Trial decision

Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20090925

Effective date: 20110513

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20110513

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20090925

Decision date: 20110513

Appeal identifier: 2009101008912

PS0901 Examination by remand of revocation
S901 Examination by remand of revocation
GRNO Decision to grant (after opposition)
PS0701 Decision of registration after remand of revocation

Patent event date: 20110601

Patent event code: PS07012S01D

Comment text: Decision to Grant Registration

Patent event date: 20110519

Patent event code: PS07011S01I

Comment text: Notice of Trial Decision (Remand of Revocation)

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20110729

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20110729

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20140710

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20140710

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20150721

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20150721

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20160714

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20160714

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20170714

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20170714

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20180713

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20180713

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20200716

Start annual number: 10

End annual number: 10

PC1801 Expiration of term

Termination date: 20210807

Termination category: Expiration of duration